Q-omics provides the consensus-scored MECOM profile across patient tissues and cancer cell-line models. MECOM expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MECOM is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, MECOM protein abundance shows 21,101 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, KIRC, and LUAD as cancer lineages where MECOM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MECOM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MECOM survival associations across molecular data types. MECOM RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MECOM RNA expression–survival associations across cancer types. High MECOM expression shows unfavorable associations in KIRP, MESO, UVM, LGG and PAAD, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MECOM RNA expression.
This table summarizes MECOM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MECOM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MECOM shows lower tumor expression in KIRC, KIRP, LUAD, LUSC and KICH and higher tumor expression in LIHC. The KIRC box plot shows higher MECOM RNA expression in normal versus tumor tissue (log2 FC = −2.925, t-test p < 0.001).
This table shows molecular features associated with MECOM in patient tissues and cancer cell lines. In patient samples, MECOM shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MECOM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
